title: MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival.
abstract: MicroRNAs are often aberrantly expressed in human neoplasms and are postulated to play a role in neoplastic initiation and progression. miR-221 and miR-222 negatively regulate expression of CDKN1B (p27) and CDKN1C (p57), two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas. We characterized miR-221 and miR-222 expression in 49 sporadic high grade ovarian carcinomas and determined whether somatic mutation or epigenetic alterations explained the differences in expression of these miRNAs. We correlated these findings with protein expression of CDKN1B and CDKN1C as assessed by immunohistochemistry. Expression of miR-221 and miR-222 were closely correlated with each other (P = 0.0001). Interestingly, a lower ratio of miR-221 to miR-222 expression was significantly correlated with worse overall survival (P = 0.01) and remained a significant predictor of overall survival in multivariate analysis using the covariate adequacy of surgical cytoreduction (P = 0.03). Higher miR-222 and miR-221 expression were significantly associated with decreased CDKN1C expression (P = 0.009 and 0.01). In contrast, CDKN1B expression was not associated with miR-221 or miR-222 expression. Neither somatic mutations nor methylation of the studied region explained the alterations in miR-221 and miR-222 expression in most carcinomas.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195-6460, USA.
authors.forename: Kaitlyn
authors.initials: K
authors.lastname: Wurz
authors.forename: Rochelle L
authors.initials: RL
authors.lastname: Garcia
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Goff
authors.forename: Patrick S
authors.initials: PS
authors.lastname: Mitchell
authors.forename: Jun Haeng
authors.initials: JH
authors.lastname: Lee
authors.forename: Muneesh
authors.initials: M
authors.lastname: Tewari
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Swisher
mesh_terms: D002453:Cell Cycle / Q000235:genetics; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000235:genetics; D050761:Cyclin-Dependent Kinase Inhibitor p57; D018450:Disease Progression; D015536:Down-Regulation; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D014158:Transcription, Genetic
chemical_list: D050760:Cyclin-Dependent Kinase Inhibitor p27; D050761:Cyclin-Dependent Kinase Inhibitor p57; D035683:MicroRNAs; C493964:CDKN1C protein, human; C525709:MIR221, human; C525710:MIR222, human
references.citation: EMBO J. 2007 Aug 8;26(15):3699-708
references.pmid: 17627278
references.citation: Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41
references.pmid: 16754881
references.citation: Int J Gynecol Pathol. 2007 Oct;26(4):418-25
references.pmid: 17885492
references.citation: N Engl J Med. 2008 Dec 18;359(25):2641-50
references.pmid: 19092150
references.citation: Hum Pathol. 2001 Aug;32(8):808-13
references.pmid: 11521224
references.citation: Cancer Res. 2007 Sep 15;67(18):8699-707
references.pmid: 17875710
references.citation: Nucleic Acids Res. 2005 May 12;33(8):2697-706
references.pmid: 15891114
references.citation: Oncogene. 2008 Sep 25;27(43):5651-61
references.pmid: 18521080
references.citation: Clin Cancer Res. 2003 Oct 15;9(13):4811-8
references.pmid: 14581352
references.citation: Cancer Res. 2008 Apr 15;68(8):2773-80
references.pmid: 18413744
references.citation: Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9
references.pmid: 18458333
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61
references.pmid: 18768788
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: Cell Cycle. 2007 Aug 15;6(16):2005-9
references.pmid: 17721077
references.citation: Clin Cancer Res. 1999 Oct;5(10):2848-53
references.pmid: 10537352
references.citation: Gynecol Oncol. 1999 May;73(2):202-9
references.pmid: 10329035
references.citation: Anticancer Res. 2002 Nov-Dec;22(6A):3191-6
references.pmid: 12530064
references.citation: Cancer Res. 1999 Aug 1;59(15):3790-4
references.pmid: 10446997
references.citation: PLoS One. 2008 Jun 18;3(6):e2436
references.pmid: 18560586
references.citation: BMC Cancer. 2008 Mar 06;8:68
references.pmid: 18325103
references.citation: Cell. 2009 Jan 23;136(2):215-33
references.pmid: 19167326
references.citation: PLoS One. 2009;4(4):e5311
references.pmid: 19390579
references.citation: Trends Mol Med. 2006 Dec;12(12):580-7
references.pmid: 17071139